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primarily catalyzes the conversion of Ang II into Ang-(1-7), 10 thereby contributing to the balance between the 2 peptides and, consequently, it is a key modulator of the 2 axes of the renin-angiotensin system. 6 The role of the ACE/Ang II/AT 1 axis in the development and progression of the endothelial dysfunction is well recognized, especially in terms of ROS production by endothelial and vascular smooth muscle cells. 3, 4, 7 Treatment with free radical scavengers, such as superoxide dismutase, catalase, and tempol, reduces blood pressure and vascular damage in response to Ang II. 12, 13 Moreover, it was reported that activation of the ACE2/Ang-(1-7)/Mas axis ameliorates the endothelial function in many animal models. 14 Indeed, short-term infusion of Ang-(1-7) improved endothelial response to acetylcholine, 15 and Mas deficiency caused endothelial dysfunction and increases in blood pressure associated with elevation of the ROS production. 16 Altogether, these findings led us to postulate that activation of intrinsic ACE2 would improve endothelial dysfunction by decreasing the production of ROS. To test this hypothesis, we evaluated the effects of 1-[[2-(dimetilamino)etil]amino]-4-(hidroximetil)-7-[[(4-metilfenil)sulfonil]oxi]-9H-xantona-9 (XNT), a small molecule that has been reported to activate intrinsic ACE2, 17 on endothelial dysfunction. XNT was discovered on the basis of crystal structure of ACE2 using a virtual screening strategy. 17 Administration of this compound in spontaneously hypertensive rats (SHRs) decreased blood pressure, improved cardiac function, and reversed myocardial and perivascular fibrosis through a mechanism involving reductions in extracellular signal-regulated kinases expression. 17, 18 Moreover, XNT reduced pulmonary hypertension induced by monocrotaline, 19 attenuated thrombus formation and platelet attachment to vessels of hypertensive rats, 20 and ameliorated cardiac and autonomic function of diabetic rats. 21, 22 
Methods
The procedures used for the measurement of ACE2 activity, isolated aortic ring preparation, radioimmunoassay, Western blotting, and immunohistochemistry are described in the online-only Data Supplement.
Animals
Male Sprague-Dawley rats and SHRs (12 weeks of age) were purchased from Charles River Laboratories (Wilmington, MA). Male Wistar rats (12 weeks of age) were obtained from the CEBIO-Federal University of Minas Gerais (Belo Horizonte, MG, Brazil). Male wildtype (Mas +/+ ) and Mas knockout (Mas −/− ) mice (FVB/N background, 12 weeks of age) were bred at the transgenic animal facility of the Laboratory of Hypertension, Federal University of Minas Gerais (Belo Horizonte, MG, Brazil). All animals were kept in temperature-controlled rooms with 12/12-hour light/dark cycle and had free access to water and food. All experimental protocols were performed in accordance with the University of Florida (Gainesville, FL) and the Federal University of Minas Gerais (Brazil) Institutional Animal Care and Use Committees, which are in compliance with the National Institutes of Health guidelines.
Statistical Analysis
The results are presented as mean±SEM. Two-way ANOVA with Bonferroni multiple comparison post test was used to compare the curves obtained in the ACE2 activity and aortic ring preparation protocols. In addition, 1-way ANOVA followed by the Bonferroni post test was used to analyze the Western blotting, immunohistochemistry, and ROS production data, and Student t test was used to analyze the radioimmunoassay results. All statistical analyses were considered significant when P<0.05.
Results

XNT Improves Endothelial Function of SHRs and Diabetic Rats
In accordance with previous studies by Hernández Prada et al, 17 we observed that incubation of rhACE2 with XNT in vitro increased the activity of ACE2, thereby confirming the ability of XNT to activate this enzyme ( Figure S1 in the online-only Data Supplement). Similar data were observed when aortic samples from normal and diabetic animals were incubated with the fluorogenic substrate ( Figure S2 ). As a consequence, ACE2 activation significantly increased the concentration of Ang-(1-7) in plasma of diabetic animals, but not in aorta ( Figure S3 ). Although ≈30% of decrease in plasma Ang II levels was observed in diabetic-treated rats, it did not reach statistical significance ( Figure S4 ). Importantly, the ACE2 activity in diabetic rats was significantly lower when compared with normal animals ( Figure S2 ). Treatment with XNT was unable to change the ACE2 protein expression in diabetic rats ( Figures S5 and S6) .
To examine the effects of chronic XNT treatment on the endothelial function, the vasorelaxant responses to ACh (acetylcholine) and SNP (sodium nitroprusside) were evaluated in aortic rings from hypertensive and diabetic rats. The vasodilatory responses to ACh were markedly enhanced in both SHRs ( Figure  1A ) and diabetic Wistar rats ( Figure 1B ) treated with XNT. In contrast, the endothelial-independent responses to SNP were not affected by XNT when compared with vessels from untreated SHRs ( Figure 1C ) and diabetic rats ( Figure 1D ). These results showed that the endothelium-dependent vascular responses were improved by ACE2 activation in SHRs and diabetic rats.
XNT Produces Vasorelaxant Responses Associated With Mas Activation
XNT caused concentration-dependent vasorelaxation in aortic rings of Sprague-Dawley rats preconstricted with phenylephrine ( Figure 2A ). Using the submaximal concentration of 10 μmol/L, XNT promoted a time-dependent vasorelaxation with maximal effect reached after 7 minutes ( Figure 2B ). To evaluate the participation of the endothelium in the vasorelaxant effects of XNT, aortic rings of rats with or without intact endothelium were incubated with this compound. It was found that the XNT effects were dependent on the endothelial cells ( Figure 2C ).
To address the mechanism by which XNT produces vasorelaxation, the vessels were preincubated with 2 different Mas antagonists. It was observed that the vasorelaxant effect of XNT was attenuated by D-pro7-Ang-(1-7) (10 μmol/L; Figure  2D ). Interestingly, preincubation with A-779 (10 μmol/L), a classical Mas antagonist, did not change its vasorelaxant activity ( Figure 2E ). On the basis of possible participation of Mas in the vasorelaxant effects of XNT, we further evaluated the actions of this compound in vessels of Mas −/− mice. We found that XNT at 10 μmol/L caused similar vasorelaxation in Mas −/− and Mas +/+ mice during the first 5 minutes of incubation. However, after this initial period the XNT effect was absent in Mas −/− mice when compared with Mas +/+ mice ( Figure 2F ). The initial vasodilatory effect observed in Mas −/− mice was not associated with Ang II degradation by ACE2 because incubation with losartan did not affect the vasodilator response of XNT ( Figures 2G and 2H ).
XNT Attenuates Oxidative Stress
Consistent evidences indicate that ROS play an important role in the development of endothelial dysfunction. Thus, we investigated the participation of the oxidative stress in the effects of XNT on the endothelial function of diabetic Wistar rats. Specifically, we evaluated the ROS production in aortic vessels of diabetic animals. Diabetes mellitus caused an increase in the generation of ROS, which was significantly reduced by XNT treatment (Figure 3 ). No significant changes were observed in the expression of catalase, superoxide dismutase, and NOX2 in aorta of diabetic rats treated or not with XNT ( Figure S7) .
In addition, we tested whether XNT is able to reduce the Ang II-inducing ROS production in human aortic endothelial cells. It was observed that XNT treatment attenuated the ROS production stimulated by Ang II. XNT alone did not change the basal level of ROS ( Figure S8 ).
Discussion
The beneficial role of ACE2 in the pathophysiology of cardiovascular and metabolic diseases is currently under intensive investigation. In fact, the involvement of this enzyme in cardiac function, hypertension, atherosclerosis, and other cardiovascular diseases has recently been demonstrated. 6, [17] [18] [19] [20] [23] [24] [25] [26] [27] The most significant finding of the present study is that pharmacological ACE2 activation using XNT exerts protective effects on endothelial function. Furthermore, we showed that this action involves the Mas receptor and reduction of ROS production.
As the main ACE2 enzymatic function is degrading Ang II with consequent production of Ang-(1-7), the likely mechanism underlying the XNT effects is balancing the bioavailability of these 2 peptides. Indeed, we observed that the Mas antagonist D-pro7-Ang-(1-7) attenuated the vasorelaxant response elicited by XNT, thereby indicating the involvement of Ang-(1-7)/Mas in this effect. Unexpectedly, A-779, a classical Mas antagonist, did not affect this action. In spite of these apparent contradictory results, these findings are in keeping with previous studies showing that the vasorelaxant effect of Ang-(1-7) in aortic rings of Sprague-Dawley rats was blocked by D-pro7-Ang-(1-7) but not by A-779. 28 Nowadays, there is only 1 Ang-(1-7) receptor identified (ie, Mas receptor). 8 Usually, this receptor is blocked by A-779 and D-pro7-Ang-(1-7). 29 However, as mentioned above, in certain situations one of these antagonists is not efficient or is only partially effective in blocking the Ang-(1-7) effects. 28 This strongly suggests the existence of other unidentified Ang-(1-7) receptors. To further evaluate the role of Ang-(1-7)/Mas in the effects of XNT, we measured the plasma and aortic Ang-(1-7) levels and tested the XNT effects in isolated aortic rings of Mas-deficient mice. It was observed that ACE2 activation significantly increased the concentration of this peptide in the plasma. The results obtained in Mas −/− mice showed that, during the first 5 minutes of incubation, XNT induced vasorelaxation in Mas −/− and Mas +/+ mice. However, after 10 minutes the effects of XNT were absent in Mas −/− , indicating that Mas is involved in the vascular response of XNT. One may suggest that the initial vasodilatory effect observed in Mas −/− mice is caused by degradation of Ang II by ACE2. Nevertheless, this hypothesis is not plausible because incubation of XNT associated with losartan did not block this vasodilatory response. Therefore, further experiments are required to explain this observation. Altogether, these findings The partial blockade (≈50%) of the XNT actions by D-pro7-Ang-(1-7) was an expected finding because ACE2 is an enzyme with a dual role within the renin-angiotensin system (ie, it degrades Ang II with consequent production of Ang- (1-7) ). Thus, the residual effect of XNT in the presence of D-pro7-Ang-(1-7) might be caused by the reduction of the Ang II content. However, we did not observe any significant decrease in plasma Ang II levels in diabetic rats treated with XNT. Furthermore, increases in ACE2 protein and mRNA expression are a frequent finding when using ACE2 activators. 18 This suggests that these compounds not only induce their beneficial effects by forming Ang-(1-7) and degrading Ang II, but a nonidentified mechanism is also present.
Nevertheless, in our study, XNT was unable to increase the ACE2 protein expression maybe because of the duration of the experimental protocol. Thus, further investigations are necessary to clearly identify the mechanisms of action of XNT.
The ROS are intracellular and intercellular second messengers that modulate the endothelial function. 30 Under pathological conditions, elevation of the ROS content, the so-called oxidative stress, results in vascular dysfunction. 31 In fact, consistent evidences indicate that ROS play an important role in the development of organ damage in diabetes mellitus and hypertension. 30, 32 Ang II elicits many of its pathophysiological effects by stimulating ROS generation through the reduction of the nicotinamide adenine dinucleotide phosphate oxidase activity. Moreover, treatment with free radical scavengers, such as superoxide dismutase, catalase, and tempol, reduces the vascular damage in response to Ang II. 12, 13 In contrast, it has been reported that Ang-(1-7) via Mas ameliorates endothelial dysfunction in animal models by decreasing the oxidative stress. [14] [15] [16] In accordance with these findings, we showed that chronic treatment with XNT reduced the ROS content in aorta of diabetic rats to a similar level observed in nondiabetic animals. In addition, XNT treatment was also able to reduce the Ang II-induced ROS production in human aortic endothelial cells. No significant changes were observed in the aortic expression of catalase, superoxide dismutase, and NOX2 among any of the groups. Taking into account that these enzymes are critical ROS scavengers, our results suggest that the modulation of the expression of these enzymes is not a mechanism by which XNT reduces the ROS production in aorta. Moreover, it is pertinent to note that the effects of XNT on ROS generation must be evaluated under in vivo condition to further confirm the association between XNT treatment and oxidative stress reduction.
In attempting to explain the mechanisms by which XNT improves the endothelial function of diabetic rats, acute experiments evaluating the role of the endothelium and Mas receptor were run in rings extracted from normal animals. Thus, the translation of these data obtained in normal rats to diabetic and hypertensive animals must be done carefully. However, they are an evidence of the mechanisms involved in the beneficial endothelial actions of XNT in these pathological conditions.
Also, the hypertensive model was less explored in our study and it was used with the intention of adding more generality to our data.
Perspectives
Our present study demonstrated that XNT improves the endothelial function of hypertensive and diabetic rats. These actions involved the Mas receptor and reduction of ROS production. Thus, these results indicate that pharmacological ACE2 activation by XNT promotes beneficial effects on the endothelial function and that this compound is a lead molecule to develop potential therapeutic strategies and drugs to treat cardiovascular and metabolic diseases by improving the endothelial function.
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• The balance between release and function of endothelium-derived nitric oxide and reactive oxygen species production is critical in endothelial dysfunction. Therapies targeting the reestablishment of this balance might have significant implications in hypertension and cardiovascular disease management. Thus, our study proposes angiotensin-converting enzyme 2 activation as a potential target for treating hypertension and related cardiovascular diseases.
METHODS
Experimental Model of Diabetes
Diabetes was induced in Wistar rats using streptozotocin (STZ; Sigma-Aldrich, USA; Cat# S0130), as described elsewhere. 1 Briefly, anesthetized rats (100mg/kg ketamine and 10mg/kg xylazine) were injected with STZ (50mg/kg), intravenously. The animals were deprived of food twelve hours before the STZ injection. After ten days, blood glucose levels were measured using a glucometer and the treatment with XNT (1mg/kg per day, during four weeks, gavage) was initiated. At the end of the XNT treatment, the measurement of the blood glucose levels was repeated and the animals were sacrificed.
Isolated Aortic Rings Preparation
Isolated aortic rings were used to evaluate the acute and chronic (SHR and diabetic animals) vascular effects of XNT. Aortic rings (4mm) from the descending thoracic aorta, free of adipose and connective tissues, were set up in gassed (95%O 2 and 5%CO 2 ) Krebs-Henseleit solution (110.8mmol/L NaCl, 5.9mmol/L KCl, 25.0mmol/L NaHCO 3 , 1.1mmol/L MgSO 4 , 2.5mmol/L CaCl 2 , 2.3mmol/L NaH 2 PO 4 and 11.5mmol/L glucose) at 37 o C under a tension of 1g for 1 hour to equilibrate. The vessels from mice were stabilized with 0.5g of tension. Mechanical activity was recorded isometrically using a force transducer (World Precision Instruments, USA), amplified (Model TMB-4; World Precision Instruments, USA) and stored in a personal computer equipped with an analogue-to-digital converter board (AD16JR; World Precision Instruments, USA) utilizing the CVMS data acquisition/recording software (World Precision Instruments, USA). The effects of XNT were evaluated in aortic rings pre-constricted with phenylephrine (0.1µmol/L). In the acute protocols (Sprague-Dawley rats, n=8 to 10), XNT was added into the bath in increasing cumulative concentrations (0.1nmol/L to 100µmol/L) or as an unique submaximal concentration (10µmol/L) after the stabilization of the response to phenylephrine. To evaluate the role of Mas, D-pro 7 -Ang-(1-7) (1µmol/L and 10µmol/L) or A-779 (10µmol/L) was added into the bath associated to the XNT (10µmol/L). Aortic rings of Mas +/+ and Mas -/mice were incubated with the submaximal concentration (10µmol/L) of XNT in the absence or presence of losartan after the stabilization of the response to phenylephrine. In addition, the acetylcholine (ACh, at 1nmol/L to 1µmol/L) and sodium nitroprusside (SNP, at 1nmol/L to 1µmol/L) vasorelaxant responses were used to evaluate the endothelial function of chronically XNT-treated SHR (1mg/kg per day, for four weeks, osmotic minipumps, model 2ML4-Alzet ® ) and of chronically XNT-treated diabetic rats (Wistar rats, 1mg/kg per day, four weeks, gavage). Also, the participation of the endothelium in the vasorelaxant effects of XNT was examined by incubating this compound with aortic rings from normal Wistar rats with or without intact endothelium.
Measurement of ACE2 Activity
The enzymatic activity (n=5) of human recombinant ACE2 (rhACE2; R&D systems, USA; Cat# 933-ZN) and of aorta samples from normal and diabetic animals (n=6-8) was determined using a fluorogenic substrate (fluorogenic peptide VI; R&D systems, USA; Cat# ES007) in the presence or absence of XNT. Enzymatic activity was measured with a Spectra Max Gemini EM Fluorescence Reader (Molecular Devices, USA), as previously described. 2, 3 Samples were read every 30 seconds for, at least, 40 minutes immediately after the addition of the fluorogenic peptide substrate at 37°C. The data obtained using tissue samples were represented as the average of all readings. Figure S4 . Plasma Ang II levels in diabetic (STZ) rats treated or not with XNT. No significant changes were observed between the groups (Student t-test).
Supplemental Figure S5 . Angiotensin-converting enzyme 2 (ACE2) protein expression in aorta of control (non-diabetic) and diabetic rats treated or not with XNT. Representative blot and quantification of the expression. A total of 30µg of protein was applied to the gel. Data were normalized using GAPDH. One-way ANOVA followed by the Bonferroni's multiple comparison test. The data are presented as mean ± SEM (n=4 to 5). Figure S7 . Catalase, superoxide dismutase (SOD) and NOX2 protein expression in aorta of diabetic rats. Representative blots and quantification of the expression of (A) catalase, (B) SOD and (C) NOX2 in aorta of control (non-diabetic) and diabetic rats treated or not with XNT. For each blot a total of 30µg of protein was applied to the gel. Data were normalized using GAPDH. One-way ANOVA followed by the Bonferroni's multiple comparison test. The data are presented as mean ± SEM (n=6 to 10).
